Finally, SVB Leerink decreased their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th.

Source: https://www.americanbankingnews.com/2023/02/14/alphacore-capital-llc-has-1-16-million-stock-holdings-in-johnson-johnson-nysejnj.html

Finally, SVB Leerink raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, March 27th.

Source: https://www.americanbankingnews.com/2023/04/05/greenleaf-trust-has-1-40-million-holdings-in-regeneron-pharmaceuticals-inc-nasdaqregn.html

Finally, SVB Leerink started coverage on shares of Intuitive Surgical in a research report on Monday, October 16th.

Source: https://www.dailypolitical.com/2023/12/11/bayesian-capital-management-lp-takes-4-35-million-position-in-intuitive-surgical-inc-nasdaqisrg.html

SVB Leerink boosted their target price on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, January 12th.

Source: https://www.etfdailynews.com/2023/01/30/ieq-capital-llc-buys-new-shares-in-hologic-inc-nasdaqholx/

SVB Leerink cut their target price on 2seventy bio from $41.00 to $34.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 10th.

Source: https://www.etfdailynews.com/2023/02/07/barclays-plc-raises-stock-holdings-in-2seventy-bio-inc-nasdaqtsvt/

SVB Leerink cut their target price on shares of BridgeBio Pharma from $23.00 to $19.00 and set an “outperform” rating for the company in a report on Monday, January 23rd.

Source: https://www.dailypolitical.com/2023/02/06/bridgebio-pharma-inc-nasdaqbbio-ceo-neil-kumar-sells-120000-shares.html

SVB Leerink decreased their price target on Pediatrix Medical Group from $20.00 to $16.00 and set a “market perform” rating for the company in a report on Friday, November 4th.

Source: https://www.etfdailynews.com/2023/01/28/pediatrix-medical-group-inc-nysemd-shares-sold-by-sg-americas-securities-llc/

SVB Leerink decreased their price target on shares of AbbVie from $140.00 to $135.00 and set an “underperform” rating for the company in a research note on Friday, September 30th.

Source: https://www.americanbankingnews.com/2023/01/01/amica-retiree-medical-trust-purchases-1127-shares-of-abbvie-inc-nyseabbv.html

SVB Leerink dropped their target price on shares of Aurinia Pharmaceuticals from $17.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 4th.

Source: https://www.etfdailynews.com/2023/02/01/allspring-global-investments-holdings-llc-purchases-new-stake-in-aurinia-pharmaceuticals-inc-nasdaqauph/

SVB Leerink dropped their target price on shares of Blueprint Medicines from $45.00 to $38.00 and set a “market perform” rating for the company in a research report on Friday, February 24th.

Source: https://www.etfdailynews.com/2023/03/08/blueprint-medicines-co-nasdaqbpmc-shares-sold-by-nuveen-asset-management-llc/

SVB Leerink raised their price target on shares of Amgen from $256.00 to $282.00 and gave the company a “market perform” rating in a report on Thursday, December 22nd.

Source: https://www.americanbankingnews.com/2023/01/05/desjardins-global-asset-management-inc-acquires-102-shares-of-amgen-inc-nasdaqamgn.html